ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Buprenorphine and naloxone: Drug information

Buprenorphine and naloxone: Drug information
(For additional information see "Buprenorphine and naloxone: Patient drug information" and see "Buprenorphine and naloxone: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Special Alerts
FDA Requiring Updates to Opioid Prescribing Information April 2023

The FDA has issued a drug safety communication to announce safety-related updates to the prescribing information for immediate-release (IR) and extended-release (ER)/long-acting (LA) opioid analgesics, including updates to Boxed Warnings, Indications and Usage, Dosage and Administration, Warnings and Precautions, and the Medication Guide. These safety labeling changes are intended to provide clarity on appropriate patient populations for opioid treatment, appropriate dosage and administration, and updated information on the risks associated with opioid use. The required safety labeling changes include stating:

  • the risk of overdose increases as the dosage increases for all opioid pain medicines;

  • IR opioids should not be used for an extended period of time unless a patient's pain remains severe enough to require them and alternative treatment options continue to be inadequate;

  • many acute pain conditions treated in the outpatient setting require no more than a few days of an opioid pain medicine;

  • it is recommended to reserve ER/LA opioid pain medicines for severe and persistent pain that requires an extended treatment period with a daily opioid pain medicine and for which alternative treatment options are inadequate; and

  • a warning about opioid-induced hyperalgesia (OIH), including information on differentiating OIH symptoms from those of opioid tolerance and withdrawal.

Further information may be found at https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use.

Brand Names: US
  • Bunavail [DSC];
  • Suboxone;
  • Zubsolv
Brand Names: Canada
  • PMS-Buprenorphine-Naloxone;
  • Suboxone;
  • TEVA-Buprenorphine/Naloxone
Pharmacologic Category
  • Analgesic, Opioid;
  • Analgesic, Opioid Partial Agonist
Dosing: Adult
Opioid use disorder

Opioid use disorder: Note: Prior to induction, consider type of opioid use (ie, long- or short-acting opioid) and time since last use of opioid.

Patients on heroin or short-acting prescription opioids should initiate buprenorphine/naloxone when signs of opioid withdrawal occur, but no sooner than 12 hours after the last opioid use (Ref). See dosing section below on "Switching therapies" for guidance on transitioning from methadone to buprenorphine.

Despite the manufacturer's recommendation to use buprenorphine instead of buprenorphine/naloxone during the induction period for long-acting opioid dependence due to the risk of withdrawal caused by naloxone, some experts recommend the combination product or buprenorphine for induction for long- and short-acting opioids (Ref).

US labeling:

Induction:

Note:

Titrate induction dose carefully to control acute withdrawal symptoms while avoiding sedation and monitoring for onset of precipitated withdrawal symptoms. Consider lower initial doses in patients with a history of opioid use disorder with a high risk of relapse but not currently dependent on opioids; titration in these patients should occur much more slowly than tolerant patients to avoid oversedation/overdose (Ref).

Buccal film (Bunavail: Buprenorphine 2.1 mg/naloxone 0.3 mg; buprenorphine 4.2 mg/naloxone 0.7 mg; buprenorphine 6.3 mg/naloxone 1 mg): Note: Bunavail (buccal film) has been discontinued in the United States for >1 year.

Day 1 induction dose: Initial: Buccal: Buprenorphine 2.1 mg/naloxone 0.3 mg; consider an initial dose of buprenorphine ~1 mg and naloxone 0.15 mg in patients with a history of opioid use disorder with a high risk of relapse but not currently dependent on opioids (Ref). May repeat dose after ~2 hours, based on control of acute withdrawal symptoms; maximum total dose: buprenorphine 4.2 mg/naloxone 0.7 mg (Ref).

Day 2 induction dose: Up to buprenorphine 8.4 mg/naloxone 1.4 mg as a single dose.

Sublingual film (Suboxone: Buprenorphine 2 mg/naloxone 0.5 mg; buprenorphine 4 mg/naloxone 1 mg; buprenorphine 8 mg/naloxone 2 mg; buprenorphine 12 mg/naloxone 3 mg):

Day 1 induction dose: Initial: Sublingual: Buprenorphine 2 mg/naloxone 0.5 mg or buprenorphine 4 mg/naloxone 1 mg; consider an initial dose of buprenorphine 1 mg and naloxone 0.25 mg in patients with a history of opioid use disorder with a high risk of relapse but not currently dependent on opioids (Ref). May titrate dose, based on control of acute withdrawal symptoms, in buprenorphine 2 mg/naloxone 0.5 mg or buprenorphine 4 mg/naloxone 1 mg increments approximately every 2 hours up to a total dose of buprenorphine 8 mg/naloxone 2 mg (Ref).

Day 2 induction dose: Sublingual: Up to buprenorphine 16 mg/naloxone 4 mg as a single dose.

Sublingual tablet (Zubsolv: Buprenorphine 0.7 mg/naloxone 0.18 mg, buprenorphine 1.4 mg/naloxone 0.36 mg, buprenorphine 2.9 mg/naloxone 0.71 mg, buprenorphine 5.7 mg/naloxone 1.4 mg, buprenorphine 8.6 mg/naloxone 2.1 mg, or buprenorphine 11.4 mg/naloxone 2.9 mg):

Day 1 induction dose: Sublingual: Start with an initial dose of buprenorphine 1.4 mg/naloxone 0.36 mg; based on control of acute withdrawal symptoms, may administer additional doses in increments of 1 to 2 buprenorphine 1.4 mg/naloxone 0.36 mg tablets every 1.5 to 2 hours to a total day 1 dose up to buprenorphine 5.7 mg/naloxone 1.4 mg. Some patients (eg, those with recent exposure to buprenorphine) may tolerate up to buprenorphine 4.2 mg/naloxone 1.08 mg as a single, second dose.

Day 2 induction dose: Sublingual: Up to buprenorphine 11.4 mg/naloxone 2.9 mg as a single dose.

Maintenance: Note: In patients with pain, temporarily increasing the dose by 20% to 25% or dosing frequency (eg, divide total daily dose over 3 to 4 times per day) may maximize the analgesic properties for pain management (Ref). Buprenorphine may be safely dosed 2 or 3 times a week instead of once daily when more convenient dosing schedules are needed; divide the total weekly dose over 2 or 3 days per week (Ref).

Buccal film (Bunavail: Buprenorphine 2.1 mg/naloxone 0.3 mg, buprenorphine 4.2 mg/naloxone 0.7 mg, buprenorphine 6.3 mg/naloxone 1 mg): Note: Bunavail (buccal film) has been discontinued in the United States for >1 year. Buccal: Target dose: Buprenorphine 8.4 mg/naloxone 1.4 mg once daily; dosage should be adjusted in increments/decrements of buprenorphine 2.1 mg/naloxone 0.3 mg to a level that maintains treatment and suppresses opioid withdrawal symptoms; usual range: Buprenorphine 2.1 to 12.6 mg/naloxone 0.3 to 2.1 mg once daily.

Sublingual film (Suboxone: Buprenorphine 2 mg/naloxone 0.5 mg; buprenorphine 4 mg/naloxone 1 mg; buprenorphine 8 mg/naloxone 2 mg; buprenorphine 12 mg/naloxone 3 mg): Sublingual or buccal: Target dose: Buprenorphine 16 mg/naloxone 4 mg once daily; dosage should be adjusted in increments/decrements of buprenorphine 2 mg/naloxone 0.5 mg or buprenorphine 4 mg/naloxone 1 mg to a level that maintains treatment and suppresses opioid withdrawal symptoms; usual range: Buprenorphine 4 to 24 mg/naloxone 1 to 6 mg once daily. Buprenorphine doses ≥16 mg/day have been associated with greater efficacy; limited evidence exists for doses >24 mg/day.

Sublingual tablet (buprenorphine 2 mg/naloxone 0.5 mg or buprenorphine 8 mg/naloxone 2 mg): Sublingual: Target dose: Buprenorphine 16 mg/naloxone 4 mg once daily; dosage should be adjusted in increments/decrements of buprenorphine 2 mg/naloxone 0.5 mg or buprenorphine 4 mg/naloxone 1 mg to a level that maintains treatment and suppresses opioid withdrawal symptoms; usual range: Buprenorphine 4 to 24 mg/naloxone 1 to 6 mg once daily. Buprenorphine doses ≥16 mg/day have been associated with greater efficacy; limited evidence exists for doses >24 mg/day.

Sublingual tablet (Zubsolv: Buprenorphine 0.7 mg/naloxone 0.18 mg, buprenorphine 1.4 mg/naloxone 0.36 mg, buprenorphine 2.9 mg/naloxone 0.71 mg, buprenorphine 5.7 mg/naloxone 1.4 mg, buprenorphine 8.6 mg/naloxone 2.1 mg, or buprenorphine 11.4 mg/naloxone 2.9 mg): Sublingual: Target dose: Buprenorphine 11.4 mg/naloxone 2.9 mg once daily; dosage should be adjusted in increments/decrements of buprenorphine 2.9 mg/naloxone 0.71 mg or lower to a level that maintains treatment and suppresses opioid withdrawal symptoms; usual range: Buprenorphine 2.9 to 17.2 mg/naloxone 0.71 to 4.2 mg once daily. Doses higher than buprenorphine 17.2 mg/naloxone 4.2 mg have not been demonstrated to provide any clinical advantage.

Switching therapies:

Sublingual tablets and sublingual film: Same dosage should be used as the previous administered product. Note: Potential for greater bioavailability with certain sublingual film strengths compared to the same strength of the sublingual tablet; monitor closely for either over- or underdosing when switching patients from one formulation to another.

Buccal film and sublingual tablets or films: Due to differences in the bioavailability of Bunavail buccal films compared to other buprenorphine/naloxone sublingual tablets, different strengths must be given to achieve equivalent doses. When switching between Bunavail and other sublingual tablets, corresponding dosage strengths are as follows:

Bunavail buprenorphine 2.1 mg/naloxone 0.3 mg = buprenorphine 4 mg/naloxone 1 mg sublingual tablets or films.

Bunavail buprenorphine 4.2 mg/naloxone 0.7 mg = buprenorphine 8 mg/naloxone 2 mg sublingual tablets or films.

Bunavail buprenorphine 6.3 mg/naloxone 1 mg = buprenorphine 12 mg/naloxone 3 mg sublingual tablets or films.

Switching between sublingual film strengths:

Systemic exposure may be different with various combinations of sublingual film strengths; pharmacists should not substitute one or more film strengths for another (eg, switching from three buprenorphine 4 mg/naloxone 1 mg films to a single buprenorphine 12 mg/naloxone 3 mg film, or vice-versa) without health care provider approval, and patients should be monitored closely for either over- or underdosing when switching between film strengths.

Switching between sublingual and buccal sites of administration (Suboxone): Systemic exposure between buccal and sublingual administration of buprenorphine/naloxone sublingual film is similar. Once induction is complete, patients can switch between buccal and sublingual administration without significant risk of under or overdosing.

Switching between sublingual tablet products: Due to differences in the bioavailability of Zubsolv sublingual tablets compared to other buprenorphine/naloxone sublingual tablets, different strengths must be given to achieve equivalent doses. When switching between Zubsolv and other sublingual tablets, corresponding dosage strengths are as follows:

Zubsolv buprenorphine 1.4 mg/naloxone 0.36 mg sublingual tablets = buprenorphine 2 mg/naloxone 0.5 mg sublingual tablets.

Zubsolv buprenorphine 2.9 mg/naloxone 0.71 mg sublingual tablets = buprenorphine 4 mg/naloxone 1 mg (as two buprenorphine 2 mg/naloxone 0.5 mg sublingual tablets).

Zubsolv buprenorphine 5.7 mg/naloxone 1.4 mg sublingual tablets = buprenorphine 8 mg/naloxone 2 mg sublingual tablets.

Zubsolv buprenorphine 8.6 mg/naloxone 2.1 mg sublingual tablet = buprenorphine 12 mg/naloxone 3 mg sublingual tablets (as one buprenorphine 8 mg/naloxone 2 mg sublingual tablets and two buprenorphine 2 mg/naloxone 0.5 mg sublingual tablets).

Zubsolv buprenorphine 11.4 mg/naloxone 2.9 mg sublingual tablet = buprenorphine 16 mg/naloxone 4 mg sublingual tablets (as two buprenorphine 8 mg/naloxone 2 mg sublingual tablets).

Buprenorphine to naltrexone: Taper the buprenorphine dose gradually and discontinue. Wait 7 to 14 days before initiating treatment with naltrexone. A naloxone challenge may be used to demonstrate an absence of physical dependence (Ref).

Buprenorphine to methadone: No time delay is required (Ref).

Methadone to buprenorphine : Taper the methadone dose gradually to 30 to 40 mg per day and remain on that dose for ≥7 days. The patient should be in mild withdrawal before starting buprenorphine; this is typically 24 to 48 hours after the last dose of methadone. Initiating buprenorphine at lower doses (eg, 2 mg) decreases risk of precipitated methadone withdrawal (Ref).

Naltrexone to buprenorphine: Begin buprenorphine ~1 day following last dose of oral naltrexone and ~28 days following last dose of IM naltrexone (Ref).

Canadian labeling: Sublingual tablet: Note: Dose based on buprenorphine content.

Induction: Day 1: Initial: 4 mg as single dose; may repeat dose if necessary depending on patient's requirement; target dose: 8 to 12 mg.

Maintenance: Day 2 and beyond: Titrate per response in increments or decrements of 2 to 8 mg; usual maintenance dose: 12 to 16 mg once daily (maximum: 24 mg/day). Upon stabilization, may consider less frequent administration of corresponding equivalent dose (eg, 16 mg every other day instead of 8 mg/day or 3 times/week dosing [eg, Monday-Wednesday-Friday] with twice the maintenance dose on Monday and Wednesday and three times the maintenance dose on Friday); continue to limit maximum dose to 24 mg/day on any single day. Note: When switching dosing to less than once daily, monitor all patients for at least 90 minutes following the initial dose of the new regimen. The less frequent dosing regimen is not recommended in patients dependent on concurrent CNS-active drugs, including ethanol.

Missed doses: Reassess patients who have missed multiple doses; initial induction doses may be required when resuming therapy.

Discontinuation of therapy: When discontinuing buprenorphine/naloxone for long-term treatment of opioid use disorder, gradually decrease the dose over several months to prevent withdrawal; do not abruptly discontinue (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been adequately studied); use with caution.

Dosing: Hepatic Impairment: Adult

Mild impairment: No dosage adjustment necessary.

Moderate impairment: Use for induction is not recommended due to risk of precipitating withdrawal. Use with caution during maintenance treatment (due to reduced clearance of buprenorphine and naloxone, use may not be appropriate) in patients inducted with buprenorphine monotherapy; monitor for buprenorphine toxicity or overdose (Ref).

Severe impairment: Avoid use (Ref).

Dosing: Older Adult

Note: Minimize opioid use in older adults unless for the management of severe acute pain. Opioids are associated with an increased risk of falls and inducing or worsening delirium in older adults (Ref).

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Buprenorphine and naloxone: Pediatric drug information")

Dosage guidance:

Dosage form information: Not all sublingual dosage forms are bioequivalent; when switching between formulations, utilize equivalent doses; the following formulations are considered equivalent: buprenorphine 8 mg sublingual tablet = buprenorphine 8 mg/naloxone 2 mg sublingual film = buprenorphine 5.7 mg/naloxone 1.4 mg sublingual tablet (Ref); see "Switching Between Dosage Forms."

Opioid use disorder

Opioid use disorder: Note: Do not start induction with buprenorphine until objective and clear signs of withdrawal are apparent (otherwise withdrawal may be precipitated). Withdrawal usually occurs 8 to 12 hours after last short-acting agonist (eg, heroin, oxycodone) and up to 24 to 72 hours after last long-acting agonist (eg, methadone). Psychosocial treatment is recommended in combination with pharmacotherapy in adolescent patients (Ref).

Sublingual tablets or film: Limited data available:

Note: Dosing is presented as buprenorphine and is based on the buprenorphine:naloxone 4:1 products (eg, Suboxone); see "Switching Between Dosage Forms" below or manufacturer's labeling for details.

Adolescents: Sublingual: Initial: Buprenorphine: 2 to 4 mg; if no signs of precipitated withdrawal after 60 to 90 minutes, may increase buprenorphine in increments of 2 to 8 mg. Once initial dose is tolerated, may increase to a dose that is clinically effective and provides 24 hours of stabilization. Usual maintenance dose range: 4 to 24 mg buprenorphine/day. Doses ≥16 mg/day have been associated with greater efficacy; however, doses >24 mg/day have not been shown to be more effective and may increase risk of diversion. Continue effective maintenance dose for as long as necessary for opioid use disorder; there are no recommended limits on duration of therapy (Ref).

Switching between dosage forms: Limited data available (Ref):

Switching between sublingual tablets and sublingual film: The same equivalent dosage should be used as the previous administered product with close patient monitoring. Note: There is potential for greater bioavailability with certain sublingual film strengths compared to the same strength of the sublingual tablet; monitor closely for either over- or underdosing when switching patients from one formulation to another.

Switching between sublingual and buccal sites of administration (Suboxone film): Systemic exposure between buccal and sublingual administration of buprenorphine/naloxone sublingual film is similar. Once induction is complete, patients can switch between buccal and sublingual administration without significant risk of under or overdosing.

Switching between sublingual film strengths: Systemic exposure may be different with various combinations of sublingual film strengths; pharmacists should not substitute one or more film strengths for another (eg, switching from three buprenorphine 4 mg/naloxone 1 mg films to a single buprenorphine 12 mg/naloxone 3 mg film, or vice-versa) without health care provider approval, and patients should be monitored closely for either over- or underdosing when switching between film strengths.

Switching between sublingual tablet products: Due to differences in the bioavailability of Zubsolv sublingual tablets compared to other buprenorphine/naloxone sublingual tablets, different strengths must be given to achieve equivalent doses. When switching between Zubsolv and other sublingual tablets, corresponding dosage strengths are as follows:

Zubsolv buprenorphine 1.4 mg/naloxone 0.36 mg sublingual tablets = buprenorphine 2 mg/naloxone 0.5 mg sublingual tablets.

Zubsolv buprenorphine 2.9 mg/naloxone 0.71 mg sublingual tablets = buprenorphine 4 mg/naloxone 1 mg sublingual tablets (as two buprenorphine 2 mg/naloxone 0.5 mg sublingual tablets).

Zubsolv buprenorphine 5.7 mg/naloxone 1.4 mg sublingual tablets = buprenorphine 8 mg/naloxone 2 mg sublingual tablets.

Zubsolv buprenorphine 8.6 mg/naloxone 2.1 mg sublingual tablets = buprenorphine 12 mg/naloxone 3 mg sublingual tablets (as one buprenorphine 8 mg/naloxone 2 mg sublingual tablet and two buprenorphine 2 mg/naloxone 0.5 mg sublingual tablets).

Zubsolv buprenorphine 11.4 mg/naloxone 2.9 mg sublingual tablets = buprenorphine 16 mg/naloxone 4 mg sublingual tablets (as two buprenorphine 8 mg/naloxone 2 mg sublingual tablets).

Discontinuation of therapy: When discontinuing buprenorphine/naloxone for long-term treatment of opioid use disorder, gradually decrease the dose over several months to prevent withdrawal; do not abruptly discontinue (Ref). A standard tapering approach does not exist; taper should be individualized based on patient response.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

Adolescents:

Mild impairment: No dosage adjustment necessary; use with caution (Ref).

Moderate impairment: Use for induction is not recommended due to risk of precipitating withdrawal. Use with caution during maintenance treatment (due to reduced clearance of buprenorphine and naloxone, use may not be appropriate) in patients inducted with buprenorphine monotherapy; monitor for buprenorphine toxicity or overdose (Ref).

Severe impairment: Avoid use (Ref).

Adverse Reactions (Significant): Considerations
Dental effects

Cases of tooth decay, dental caries (cavities), oral infections, and tooth loss have been reported with the use of transmucosal (eg, buccal, sublingual) buprenorphine-containing products in patients with and without a history of dental disease (Ref).

Mechanism: Non–dose-related; idiosyncratic; mechanism not clearly established. May be related to prolonged tooth exposure to the acidic medication formulation (Ref).

Onset: Delayed; identification of dental problems occurred a mean of 45.7 months (range: 5 to 77 months) after initiation of buprenorphine-containing transmucosal therapy in one case series (Ref).

Opioid-induced constipation

Opioid-induced constipation (OIC) is the most common subtype of opioid-induced bowel dysfunction, which is a broader term that encompasses additional GI opioid-induced adverse reactions including nausea, vomiting, and gastroesophageal reflux. Symptoms of OIC may include decreased frequency of bowel movements, straining to pass bowel movements, a sense of incomplete evacuation, and/or hard stools (Ref). Tolerance does not develop to OIC, and symptoms are reversible after discontinuation of the opioid (Ref). Buprenorphine, as a partial mu agonist, is associated with a lower incidence of OIC than morphine (Ref).

Mechanism: Time-related; mu-opioid receptor stimulation in the GI tract results in delayed gastric emptying, decreased peristalsis, decreased water and chloride secretion into the intestinal lumen, and slowed bowel motility (Ref).

Onset: Varied; changes in peristalsis may occur 5 to 25 minutes after administration of opioids (Ref). However, OIC is defined based on a 7-day period of change (Ref).

Risk factors:

• Concurrent use of other medications that cause constipation (eg, anticholinergic medications) (Ref)

Opioid-induced respiratory depression

Serious, life-threatening, or fatal opioid-induced respiratory depression (OIRD) may occur with use of buprenorphine, especially during dose escalation or with misuse (Ref). Effects may include hypoventilation, hypoxia, hypercapnia, respiratory acidosis, and reduced ventilatory responses to hypoxia and hypercapnia (Ref). Buprenorphine is a partial mu agonist, resulting in a dose-response ceiling regarding respiratory depression; however, clinically significant respiratory depression may occur (Ref). Reversal of buprenorphine-induced respiratory depression may be relatively resistant to naloxone due to its high mu-opioid receptor affinity and slow receptor dissociation kinetics. A higher naloxone bolus dose (ie, 2 to 3 mg IV), followed by a continuous infusion (ie, 4 mg/hour) and/or mechanical ventilation may be required for long-term management and stabilization (Ref).

Mechanism: Dose-related at lower doses with a ceiling effect (plateau) at higher doses; stimulation of mu-opioid receptors in the brainstem leads to suppression of the respiratory control network and depression of normal hypoxic and hypercapnic ventilatory responses (Ref).

Onset: Rapid; OIRD has been reported within 1 to 2 hours of IV and 2 to 6 hours of sublingual buprenorphine administration (Ref).

Risk factors:

• Initiation of therapy or dose increase

• Preexisting respiratory disease (eg, chronic obstructive pulmonary disease) (Ref)

• Concurrent benzodiazepines or other CNS depressants, including alcohol

• Acute overdose

• Older adults (Ref)

• Cardiac disease (Ref)

• Kidney and/or liver impairment (Ref)

Withdrawal, opioid-induced or precipitated

Abruptly stopping or reducing opioid use in patients with physical opioid dependence can result in opioid-induced withdrawal (OIW) (Ref). Physical symptoms may include nausea, vomiting, diarrhea, abdominal cramps, tachycardia, chills, muscle aches, bone pain, agitation, anxiety, and insomnia. Psychosis has also been described in case reports (Ref). Spontaneous withdrawal symptoms due to buprenorphine abstinence are generally milder than those experienced with full opioid agonists (Ref). Initiation of buprenorphine may cause precipitated opioid withdrawal symptoms (similar to OIW, but faster onset) (Ref) in patients currently or recently taking full mu-opioid agonists (prescribed and/or non-prescribed) for a prolonged period (Ref). Precipitated opioid withdrawal is associated with a decrease in opioid use disorder treatment retention (Ref).

Mechanism:

• OIW: Withdrawal; opioids bind to mu-opioid receptors on neurons in the locus coeruleus (LC) of the brainstem, causing decreased norepinephrine (NE) release. Upon abrupt discontinuation, the absence of opioid stimulation causes LC hyperactivity, excessive NE release, and subsequent autonomic hyperactivity (Ref).

• Precipitated opioid withdrawal: Withdrawal; buprenorphine displaces full agonists at the mu-opioid receptor (Ref). The sudden shift from full to partial opioid agonism leads to withdrawal symptoms and/or uncontrolled pain.

Onset:

• OIW: Varied; symptoms typically occur within 2 to 15 days of buprenorphine discontinuation and gradually decrease over the following 4 to 7 days (Ref).

• Precipitated opioid withdrawal: Rapid; symptoms typically occur within 30 minutes to 2 hours after buprenorphine administration and gradually decrease over the following 6 to 24 hours (Ref).

Risk factors, OIW:

• Abrupt discontinuation, rapid taper (Ref)

• Opioid use disorder (Ref)

Risk factors, precipitated opioid withdrawal:

• High level of physical opioid dependence (Ref)

• Recent fentanyl or methadone use (Ref)

• Concurrent benzodiazepine use (Ref)

• Chronic kidney disease (Ref)

• Cirrhosis (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported for the sublingual tablet in adults unless otherwise indicated. Also see individual agents.

>10%:

Dermatologic: Diaphoresis (14%)

Gastrointestinal: Abdominal pain (11%), constipation (12%) (table 1), nausea (5% to 15%) (table 2)

Buprenorphine and Naloxone: Adverse Reaction: Constipation

Drug (Buprenorphine and Naloxone)

Comparator (Buprenorphine)

Placebo

Dose

Dosage Form

Number of Patients (Buprenorphine and Naloxone)

Number of Patients (Buprenorphine)

Number of Patients (Placebo)

12%

8%

3%

16 mg buprenorphine/4 mg naloxone per day

Sublingual tablets

107

103

107

Buprenorphine and Naloxone: Adverse Reaction: Nausea

Drug (Buprenorphine and Naloxone)

Comparator (Buprenorphine)

Placebo

Dose

Dosage Form

Number of Patients (Buprenorphine and Naloxone)

Number of Patients (Buprenorphine)

Number of Patients (Placebo)

15%

14%

11%

16 mg buprenorphine/4 mg naloxone per day

Sublingual tablets

107

103

107

5%

7%

N/A

Initial dose of 1.4 mg buprenorphine/0.36 mg naloxone followed by 4.2 mg buprenorphine/1.08 mg naloxone 1.5 hours later

Sublingual tablets

538

530

N/A

Nervous system: Headache (7% to 37%), pain (22%), withdrawal syndrome (25%) (table 3)

Buprenorphine and Naloxone: Adverse Reaction: Withdrawal Syndrome

Drug (Buprenorphine and Naloxone)

Comparator (Buprenorphine)

Placebo

Dose

Dosage Form

Number of Patients (Buprenorphine and Naloxone)

Number of Patients (Buprenorphine)

Number of Patients (Placebo)

25%

18%

37%

16 mg buprenorphine/4 mg naloxone per day

Sublingual tablets

107

103

107

1% to 10%:

Cardiovascular: Vasodilation (9%)

Gastrointestinal: Oral hypoesthesia (sublingual film: >1%), vomiting (5% to 8%)

Frequency not defined:

Cardiovascular: Palpitations (sublingual film)

Dermatologic: Hyperhidrosis (sublingual film), piloerection

Gastrointestinal: Glossalgia (sublingual film), oral mucosal erythema (sublingual film), stomach discomfort

Nervous system: Anxiety, disturbance in attention (sublingual film), insomnia (sublingual film), intoxicated feeling (sublingual film), irritability, restlessness

Neuromuscular & skeletal: Arthralgia

Ophthalmic: Blurred vision (sublingual film), increased lacrimation

Respiratory: Rhinorrhea

Postmarketing (any route):

Cardiovascular: Peripheral edema

Dermatologic: Skin rash, urticaria

Gastrointestinal: Dental caries (including tooth fracture, tooth loss) (Suzuki 2012), glossitis, oral bullae, oral mucosa ulcer, stomatitis

Hypersensitivity: Anaphylactic shock, angioedema

Nervous system: Allodynia (opioid-induced hyperalgesia) (FDA Safety Communication 2023)

Respiratory: Bronchospasm

Contraindications

Hypersensitivity (eg, anaphylactic shock) to buprenorphine, naloxone, or any component of the formulation.

Canadian labeling (sublingual tablets): Additional contraindications (not in US labeling): Opioid-naive patients; severe respiratory insufficiency (eg, acute or severe bronchial asthma, chronic obstructive airway, status asthmaticus, acute respiratory depression, cor pulmonale); severe hepatic impairment; acute alcohol intoxication or delirium tremens; convulsive or seizure disorders; known or suspected mechanical GI obstruction or diseases/conditions that affect bowel transit (eg, ileus of any type); suspected surgical abdomen (eg, acute appendicitis or pancreatitis); severe CNS depression, increased cerebrospinal or intracranial pressure, or head injury; concurrent use or within 2 weeks of MAO inhibitors.

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Warnings/Precautions

Concerns related to adverse effects:

• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).

• Hepatic events: Hepatitis has been reported; hepatic events ranged from transient, asymptomatic transaminase elevations to hepatic failure; in many cases, patients had preexisting hepatic impairment. Monitor liver function tests in patients at increased risk for hepatotoxicity (eg, history of alcohol or IV drug abuse, preexisting hepatic dysfunction) prior to and during therapy.

• Hypersensitivity reactions: Hypersensitivity, including bronchospasm, angioneurotic edema, and anaphylactic shock, have been reported.

• Hypotension: May cause severe hypotension, including orthostatic hypotension and syncope; use with caution in patients with hypovolemia, cardiovascular disease (including acute myocardial infarction [MI]), or drugs that may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration. Use with caution in patients with circulatory shock.

• QT prolongation: Buprenorphine has been observed to cause QTc prolongation. Avoid using in patients with a personal or family history of long QT syndrome or in patients taking concurrent class IA or III antiarrhythmics or other medications that prolong the QT interval. Use with caution in patients with hypokalemia, hypomagnesemia, or clinically unstable cardiac disease, including unstable heart failure, unstable atrial fibrillation, symptomatic bradycardia, or active MI.

Disease-related concerns:

• Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.

• Adrenocortical insufficiency: Use with caution in patients with adrenal insufficiency, including Addison disease. Long-term opioid use may cause secondary hypogonadism, which may lead to mood disorders and osteoporosis (Brennan 2013).

• Biliary tract impairment: Use with caution in patients with biliary tract dysfunction, including acute pancreatitis.

• Bowel obstruction: Use with caution in patients with a history of ileus or bowel obstruction.

• CNS depression/coma: Use with caution in patients with impaired consciousness or coma because these patients are susceptible to intracranial effects of CO2 retention.

• Delirium tremens: Use with caution in patients with delirium tremens.

• Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur. Buprenorphine can produce miosis and changes in the level of consciousness that may interfere with patient evaluation.

• Hepatic impairment: Use is not recommended in patients with moderate hepatic impairment for induction therapy (Suboxone) or in patients with severe hepatic impairment. Use with caution in patients with moderate hepatic impairment for maintenance treatment; due to reduced clearance of naloxone and potential for reduced buprenorphine efficacy, use may not be appropriate.

• Obesity: Use with caution in patients who are morbidly obese (DeVido 2015).

• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.

• Psychosis: Use with caution in patients with toxic psychosis.

• Respiratory disease: Use with caution and monitor for respiratory depression in patients with significant chronic obstructive pulmonary disease, cor pulmonale, or kyphoscoliosis, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression, particularly when initiating and titrating therapy; critical respiratory depression may occur, even at therapeutic dosages.

• Seizure: Use with caution in patients with a history of seizure disorders; may cause or exacerbate preexisting seizures.

• Sleep-related disorders: Use with caution in patients with sleep-related disorders, including sleep apnea, due to increased risk for respiratory and CNS depression. Monitor carefully and titrate dosage cautiously in patients with mild sleep-disordered breathing. Avoid opioids in patients with moderate to severe sleep-disordered breathing (CDC [Dowell 2022]).

• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.

Concurrent drug therapy issues:

• Benzodiazepines and other CNS depressants: Concomitant use may result in respiratory depression and sedation, which may be fatal. Consider prescribing naloxone for emergency treatment of opioid overdose in patients taking benzodiazepines or other CNS depressants concomitantly with opioids.

Special populations:

• Older adult: Use opioids with caution in older adults; may be more sensitive to adverse effects. Clearance may also be reduced in older adults (with or without renal impairment) resulting in a narrow therapeutic window and increased adverse effects. Monitor closely for adverse effects associated with opioid therapy (eg, respiratory and CNS depression, falls, cognitive impairment, constipation) (CDC [Dowell 2022]). Consider the use of alternative nonopioid analgesics in these patients when possible.

• Neonates: Neonatal withdrawal syndrome: Prolonged use of opioids during pregnancy can cause neonatal withdrawal syndrome, which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant patient, advise the patient of the risk of neonatal withdrawal syndrome and ensure that appropriate treatment will be available. Signs and symptoms include irritability, hyperactivity and abnormal sleep pattern, high-pitched cry, tremor, vomiting, diarrhea, and failure to gain weight. Onset, duration, and severity depend on the drug used, duration of use, maternal dose, and rate of drug elimination by the newborn.

Special handling:

• Disposal: Dispose of unused buccal and sublingual films (if they are no longer needed) by removing from foil patch and flushing down the toilet. If multiple films are no longer needed, flush each film individually.

Other warnings/precautions:

• Accidental ingestion: Accidental ingestion in children can result in severe respiratory depression (may be fatal); store buprenorphine-containing medications out of reach of children and dispose of unused medication appropriately.

• Acute pain: When using buprenorphine for treatment of opioid use disorder, treat acute pain with nonopioid analgesics whenever possible. Dividing buprenorphine daily dose into 3 divided doses may also provide sufficient pain relief (SAMHSA 2021). If treatment with a high-affinity full opioid analgesic is required, monitor closely for respiratory depression because high doses may be necessary to achieve pain relief.

• Abuse/misuse/substance use disorder: Use exposes patients and other users to the risks of substance use disorder, abuse, and misuse, potentially leading to overdose and death. Assess each patient's risk prior to prescribing; monitor all patients regularly for development of these behaviors or conditions. Use with caution in patients with a history of substance abuse disorder; potential for drug dependency exists. Other factors associated with increased risk for misuse include concomitant depression or other mental health conditions, higher opioid dosages, or taking other CNS depressants (CDC [Dowell 2022]).

• Appropriate use: Buprenorphine/naloxone is not appropriate for pain management; deaths have been reported in opioid-naive patients receiving oral buprenorphine for analgesia.

• Discontinuation of therapy: There is no maximum recommended duration for maintenance treatment of opioid use disorder; patients may require treatment indefinitely. Advise patients of the potential to relapse to illicit drug use following discontinuation of opioid agonist/partial agonist medication-based opioid use disorder treatment.

• Naloxone access: Discuss the availability of naloxone with all patients who are prescribed opioid analgesics, as well as their caregivers, and consider prescribing it to patients who are at increased risk of opioid overdose. These include patients who are also taking benzodiazepines or other CNS depressants, have an opioid use disorder (OUD) (current or history of) or substance use disorder, and have higher opioid dosages (≥50 morphine milligram equivalents/day orally) (CDC [Dowell 2022]), or have experienced opioid-induced respiratory depression/opioid overdose. Additionally, health care providers should consider prescribing naloxone to patients prescribed medications to treat OUD; patients at risk of opioid overdose even if they are not taking an opioid analgesic or medication to treat OUD; and patients taking opioids, including methadone or buprenorphine for OUD, if they have household members, including children, or other close contacts at risk for accidental ingestion or opioid overdose. Inform patients and caregivers on options for obtaining naloxone (eg, by prescription, directly from a pharmacist, a community-based program) as permitted by state dispensing and prescribing guidelines. Educate patients and caregivers on how to recognize respiratory depression, proper administration of naloxone, and getting emergency help.

• Partial opioid agonist and mixed opioid agonist/antagonist overdose: Reversal of partial opioid agonists or mixed opioid agonist/antagonists (eg, buprenorphine, pentazocine) may be incomplete and higher than normal doses and repeated administration of naloxone may be required.

• Surgery: In patients undergoing elective surgery (excluding caesarean section), consider discontinuation of buprenorphine the day before or day of surgery. In patients unable to abruptly discontinue buprenorphine prior to surgery, full opioid agonists may be added to the buprenorphine to maintain proper analgesia. If opioid therapy is required as part of analgesia, patients should be continuously monitored in an anesthesia care setting by persons not involved in in the conduct of the surgical or diagnostic procedure. The decision whether to discontinue buprenorphine prior to elective surgery should be made in consultation with the surgeon and anesthesiologist. If discontinued, buprenorphine can be resumed postoperatively when there is no longer a need for full opioid agonist therapy; in general, presurgery daily doses may be resumed if held for <2 to 3 days (ASAM 2020).

Product Availability

Bunavail (buccal film) has been discontinued in the United States for >1 year.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Film, Buccal:

Bunavail: Buprenorphine 6.3 mg and naloxone 1 mg (1 ea [DSC], 30 ea [DSC]); Buprenorphine 2.1 mg and naloxone 0.3 mg (1 ea [DSC], 30 ea [DSC]); Buprenorphine 4.2 mg and naloxone 0.7 mg (1 ea [DSC], 30 ea [DSC]) [contains fd&c blue #1 (brilliant blue), methylparaben, propylparaben, saccharin sodium, sodium benzoate]

Film, Sublingual:

Suboxone: Buprenorphine 4 mg and naloxone 1 mg (1 ea, 30 ea); Buprenorphine 8 mg and naloxone 2 mg (1 ea, 30 ea); Buprenorphine 12 mg and naloxone 3 mg (1 ea, 30 ea); Buprenorphine 2 mg and naloxone 0.5 mg (1 ea, 30 ea) [contains fd&c yellow #6 (sunset yellow); lime flavor]

Generic: Buprenorphine 12 mg and naloxone 3 mg (1 ea, 30 ea); Buprenorphine 2 mg and naloxone 0.5 mg (1 ea, 30 ea); Buprenorphine 4 mg and naloxone 1 mg (1 ea, 30 ea); Buprenorphine 8 mg and naloxone 2 mg (1 ea, 30 ea)

Tablet Sublingual, Sublingual:

Zubsolv: Buprenorphine 5.7 mg and naloxone 1.4 mg, Buprenorphine 8.6 mg and naloxone 2.1 mg, Buprenorphine 0.7 mg and naloxone 0.18 mg, Buprenorphine 1.4 mg and naloxone 0.36 mg, Buprenorphine 11.4 mg and naloxone 2.9 mg, Buprenorphine 2.9 mg and naloxone 0.71 mg [contains menthol; menthol flavor]

Generic: Buprenorphine 2 mg and naloxone 0.5 mg, Buprenorphine 8 mg and naloxone 2 mg

Generic Equivalent Available: US

Yes

Pricing: US

Film (Buprenorphine HCl-Naloxone HCl Sublingual)

2-0.5 mg (per each): $4.91 - $5.15

4-1 mg (per each): $8.79 - $9.23

8-2 mg (per each): $8.79 - $9.23

12-3 mg (per each): $17.58 - $18.46

Film (Suboxone Sublingual)

2-0.5 mg (per each): $6.01

4-1 mg (per each): $10.78

8-2 mg (per each): $10.78

12-3 mg (per each): $21.55

Sublingual (Buprenorphine HCl-Naloxone HCl Sublingual)

2-0.5 mg (per each): $4.51 - $5.83

8-2 mg (per each): $7.88 - $10.43

Sublingual (Zubsolv Sublingual)

0.7-0.18 mg (per each): $6.12

1.4-0.36 mg (per each): $6.12

2.9-0.71 mg (per each): $12.25

5.7-1.4 mg (per each): $12.25

8.6-2.1 mg (per each): $18.37

11.4-2.9 mg (per each): $24.50

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Film, Sublingual:

Suboxone: Buprenorphine 4 mg and naloxone 1 mg (30 ea); Buprenorphine 8 mg and naloxone 2 mg (30 ea); Buprenorphine 12 mg and naloxone 3 mg (30 ea); Buprenorphine 2 mg and naloxone 0.5 mg (30 ea) [contains fd&c yellow #6 (sunset yellow)]

Tablet Sublingual, Sublingual:

Suboxone: Buprenorphine 8 mg and naloxone 2 mg, Buprenorphine 12 mg and naloxone 3 mg, Buprenorphine 16 mg and naloxone 4 mg, Buprenorphine 2 mg and naloxone 0.5 mg [contains corn starch]

Generic: Buprenorphine 2 mg and naloxone 0.5 mg, Buprenorphine 8 mg and naloxone 2 mg

Controlled Substance

C-III

Prescribing and Access Restrictions

Previously, in order to prescribe buprenorphine for opioid use disorder (OUD) in the United States, clinicians had to apply for a federally required DATA Waiver (X-Waiver). In January 2023, the Consolidated Appropriations Act of 2023 removed this requirement and allowed clinicians with schedule III authority on their Drug Enforcement Administration registration to prescribe buprenorphine for OUD treatment if permitted by applicable state law (https://www.samhsa.gov/medications-substance-use-disorders/removal-data-waiver-requirement; https://www.deadiversion.usdoj.gov/pubs/docs/index.html).

Administration: Adult

Film:

Bunavail: Buccal: Although the manufacturer recommends administering the film whole without cutting, chewing, or swallowing, one stability study (using Suboxone brand) suggested that films split in half have uniform content and maintain stability for up to 7 days (Ref). Immediately before placing the film, moisten inside of cheek with tongue or water. Apply film with a dry finger immediately after removing it from packaging. Place film with the text (BN2, BN4, or BN6) against the inside of the moistened cheek; press and hold the film in place for 5 seconds with finger (film should stay in place after this period). Keep film in place until it dissolves completely. Do not chew, swallow or move film after placement. Once film is completely dissolved, swish a sip of water around the teeth and gums and swallow; wait at least 1 hour after administration to brush teeth. Liquids and food can be consumed after film dissolves. If using more than 1 film simultaneously, the additional film should be placed on the inside of the other cheek; no more than 2 films should be applied to the inside of one cheek at a time.

Suboxone: May be used buccally or sublingually.

Buccal: Although the manufacturer recommends administering the film whole without cutting, chewing, or swallowing, one stability study suggested that films split in half have uniform content and maintain stability for up to 7 days (Ref). Place one film on the inside of the right or left cheek. If more than one film is needed, the additional film should be placed on the inside of the opposite cheek. Keep the film on the inside of the cheek until completely dissolved. Once film is completely dissolved, swish a sip of water around the teeth and gums and swallow; wait at least 1 hour after administration to brush teeth. Do not move film after placement. If a third film is necessary, place it on the inside of the right or left cheek after the first 2 films have dissolved.

Sublingual film: Although the manufacturer recommends administering the film whole without cutting, chewing, or swallowing, one stability study suggested that films split in half have uniform content and maintain stability for up to 7 days (Ref). Place one film under the tongue until the film completely dissolves, close to the base on the left or right side. If more than one film is needed, the additional film should be placed under the tongue on the opposite side from the first film. Place the film in a manner to minimize overlapping as much as possible. Do not move film after placement. If a third film is necessary to achieve the prescribed dose, place it under the tongue on either side after the first 2 films have dissolved. Once film is completely dissolved, swish a sip of water around the teeth and gums and swallow; wait at least 1 hour after administration to brush teeth.

Sublingual tablet: Immediately after removal from blister pack, tablet should be placed under the tongue until dissolved (can take up to 10 minutes to fully dissolve (Ref)). If 2 or more tablets are needed per dose, all may be placed under the tongue at once, or 2 at a time. In patients requiring more than one sublingual tablet, place all tablets in different places under the tongue at the same time. To ensure consistent bioavailability, subsequent doses should always be taken the same way. Patients should not eat or drink anything until the tablet(s) are completely dissolved. If a sequential mode of administration is preferred, patients should follow the same manner of dosing with continued use of the product, to ensure consistency in bioavailability. Do not chew or swallow sublingual tablets. Once tablet(s) are completely dissolved, swish a sip of water around the teeth and gums and swallow; wait at least 1 hour after administration to brush teeth.

Administration: Pediatric

Film:

Note: Although the manufacturer recommends administering the film whole without cutting, chewing, or swallowing, one stability study suggested that Suboxone films split in half have uniform content and maintain stability for up to 7 days (Ref).

Buccal: Place one film on the inside of one cheek. If a second film is needed, the additional film should be placed on the inside of the opposite cheek. Keep film in place until dissolved; do not move after placement. If a third film is necessary to achieve dose, place it on the inside of one cheek after the first 2 films have dissolved. Once film is completely dissolved, swish a sip of water around the teeth and gums and swallow; wait at least 1 hour after administration to brush teeth. Do not eat or drink until film is completely dissolved. Note: Recommendation to use buccally varies by manufacturer; see manufacturer labeling for details.

Sublingual: Place one film under the tongue close to the base on the left or right side. If a second film is needed, the additional film should be placed under the tongue on the opposite side from the first film. Place the film in a manner to minimize overlapping as much as possible. Keep film in place until dissolved; do not move after placement. If a third film is necessary to achieve the prescribed dose, place it under the tongue on either side after the first 2 films have dissolved. Once film is completely dissolved, swish a sip of water around the teeth and gums and swallow; wait at least 1 hour after administration to brush teeth. Do not eat or drink until film is completely dissolved.

Sublingual tablets: Administer sublingual tablets whole; do not cut, chew, or swallow whole. Immediately after removal from blister pack, tablet should be placed under the tongue until dissolved. May take up to 10 minutes for tablet to completely dissolve (Ref). If 2 or more tablets are needed per dose, all may be placed under the tongue at once in different places under the tongue. Alternatively, 1 or 2 tablets may be completely dissolved at a time until required number of tablets has been administered. Patients should follow the same manner of dosing with continued use of the product, to ensure consistency in bioavailability. Once tablet is completely dissolved along oral mucosa, swish a sip of water around the teeth and gums and swallow; wait at least 1 hour after administration to brush teeth. Patients should not eat or drink anything until the tablet(s) are completely dissolved.

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:

Bunavail buccal film:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/205637s023s024lbl.pdf#page=33

Buprenorphine and naloxone sublingual film for sublingual or buccal administration: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022410s033,020732s019,020733s023lbl.pdf#page=32

Cassipa sublingual film:https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208042s009lbl.pdf#page=30

Suboxone sublingual film:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022410s046s047lbl.pdf#page=35

Suboxone sublingual tablet:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020733s031s032lbl.pdf#page=32

Zubsolv sublingual tablet: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204242s021s023lbl.pdf#page=20

Use: Labeled Indications

Opioid use disorder: Treatment of opioid use disorder.

General information: Buprenorphine/naloxone should be used as part of a complete treatment plan to include counseling and psychosocial support.

Medication Safety Issues
High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.

Other safety concerns:

Potential for over- or underdosing when switching among various formulations and between strengths of the sublingual films: Not all strengths of sublingual tablets and films are bioequivalent to one another. In addition, systemic exposure between the various strengths of sublingual films may be different; pharmacists should not substitute one or more film strengths for another (eg, dispense three 4 mg films for one 12 mg film, or vice-versa) without physician approval. Any patient switching between sublingual tablet and sublingual film formulation or between one or more strengths of the sublingual films should be monitored for over- or underdosing.

Metabolism/Transport Effects

Refer to individual components.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Alizapride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Alvimopan: Opioid Agonists may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation. Risk D: Consider therapy modification

Amphetamines: May enhance the analgesic effect of Opioid Agonists. Risk C: Monitor therapy

Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. Risk C: Monitor therapy

Atazanavir: Buprenorphine may decrease the serum concentration of Atazanavir. Atazanavir may increase the serum concentration of Buprenorphine. Management: Buprenorphine is not recommended in patients taking atazanavir without ritonavir. In patients taking atazanavir with ritonavir or cobicistat, monitor for opioid excess if coadministered with buprenorphine and consider buprenorphine dose reductions. Risk X: Avoid combination

Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin. Risk D: Consider therapy modification

Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromopride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromperidol: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. Risk C: Monitor therapy

Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Risk D: Consider therapy modification

Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Risk C: Monitor therapy

Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

CNS Depressants: May enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Risk D: Consider therapy modification

CYP3A4 Inducers (Moderate): May decrease the serum concentration of Buprenorphine. Risk C: Monitor therapy

CYP3A4 Inducers (Strong): May decrease the serum concentration of Buprenorphine. Risk C: Monitor therapy

CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Buprenorphine. Risk C: Monitor therapy

CYP3A4 Inhibitors (Strong): May increase the serum concentration of Buprenorphine. Risk C: Monitor therapy

Daclatasvir: May increase the serum concentration of Buprenorphine. Risk C: Monitor therapy

Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

Desmopressin: Opioid Agonists may enhance the hyponatremic effect of Desmopressin. Risk C: Monitor therapy

DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine. Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression. Risk D: Consider therapy modification

Difelikefalin: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Diuretics: Opioid Agonists may enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics. Risk C: Monitor therapy

DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Risk D: Consider therapy modification

Eluxadoline: Opioid Agonists may enhance the constipating effect of Eluxadoline. Risk X: Avoid combination

Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. Risk X: Avoid combination

Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available. Risk D: Consider therapy modification

Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Gastrointestinal Agents (Prokinetic): Opioid Agonists may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). Risk C: Monitor therapy

HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant. Risk D: Consider therapy modification

Ixabepilone: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kava Kava: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kratom: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Risk D: Consider therapy modification

Lisuride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression. Risk D: Consider therapy modification

Methylnaltrexone: May enhance the adverse/toxic effect of Opioid Antagonists. Specifically, the risk for opioid withdrawal may be increased. Risk X: Avoid combination

Metoclopramide: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Risk C: Monitor therapy

Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Monoamine Oxidase Inhibitors: Buprenorphine may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination

Nabilone: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Naldemedine: Opioid Antagonists may enhance the adverse/toxic effect of Naldemedine. Specifically, the risk for opioid withdrawal may be increased. Risk X: Avoid combination

Nalmefene: May diminish the therapeutic effect of Opioid Agonists. Management: Avoid the concomitant use of oral nalmefene and opioid agonists. Discontinue oral nalmefene 1 week prior to any anticipated use of opioid agonists. If combined, larger doses of opioid agonists will likely be required. Risk D: Consider therapy modification

Naloxegol: Opioid Antagonists may enhance the adverse/toxic effect of Naloxegol. Specifically, the risk for opioid withdrawal may be increased. Risk X: Avoid combination

Naltrexone: May diminish the therapeutic effect of Opioid Agonists. Management: Seek therapeutic alternatives to opioids. See full drug interaction monograph for detailed recommendations. Risk X: Avoid combination

Nefazodone: Opioid Agonists (metabolized by CYP3A4) may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome. Nefazodone may increase the serum concentration of Opioid Agonists (metabolized by CYP3A4). Management: If concomitant use of opioid agonists that are metabolized by CYP3A4 and nefazodone is necessary, consider dose reduction of the opioid until stable drug effects are achieved. Monitor for increased opioid effects and serotonin syndrome/serotonin toxicity. Risk D: Consider therapy modification

Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Opioid Agonists: Opioids (Mixed Agonist / Antagonist) may diminish the analgesic effect of Opioid Agonists. Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations. Risk X: Avoid combination

Opioids (Mixed Agonist / Antagonist): May diminish the therapeutic effect of Buprenorphine. This combination may also induce opioid withdrawal. Risk X: Avoid combination

Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Risk X: Avoid combination

Oxomemazine: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Risk X: Avoid combination

Pegvisomant: Opioid Agonists may diminish the therapeutic effect of Pegvisomant. Risk C: Monitor therapy

PHENobarbital: May enhance the CNS depressant effect of Buprenorphine. PHENobarbital may decrease the serum concentration of Buprenorphine. Management: Avoid use of buprenorphine and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased buprenorphine efficacy and withdrawal if combined. Risk D: Consider therapy modification

Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. Risk C: Monitor therapy

Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Risk C: Monitor therapy

Primidone: May enhance the CNS depressant effect of Buprenorphine. Primidone may decrease the serum concentration of Buprenorphine. Management: Avoid use of buprenorphine and primidone when possible. Monitor for respiratory depression/sedation. Because primidone is also a strong CYP3A4 inducer, monitor for decreased buprenorphine efficacy and withdrawal if combined. Risk D: Consider therapy modification

Procarbazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Ramosetron: Opioid Agonists may enhance the constipating effect of Ramosetron. Risk C: Monitor therapy

Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania). Risk D: Consider therapy modification

ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Risk C: Monitor therapy

Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Risk C: Monitor therapy

Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Risk C: Monitor therapy

Samidorphan: May diminish the therapeutic effect of Opioid Agonists. Risk X: Avoid combination

Serotonergic Agents (High Risk): Opioid Agonists (metabolized by CYP3A4) may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Risk D: Consider therapy modification

Somatostatin Analogs: Opioid Agonists may diminish the analgesic effect of Somatostatin Analogs. Opioid Agonists may enhance the analgesic effect of Somatostatin Analogs. Risk C: Monitor therapy

Succinylcholine: May enhance the bradycardic effect of Opioid Agonists. Risk C: Monitor therapy

Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Risk X: Avoid combination

Valerian: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider therapy modification

Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects. Risk D: Consider therapy modification

Reproductive Considerations

Pregnancy testing is recommended prior to initiating therapy for opioid use disorders (ASAM 2020; SAMHSA 2021).

Refer to individual monographs for additional information.

Pregnancy Considerations

Buprenorphine and naloxone can be detected in cord blood following maternal use of sublingual tablets; cord blood concentrations of buprenorphine and naloxone correlate with maternal serum levels (Weigand 2016).

Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant patient, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure appropriate treatment will be available.

Opioid agonist pharmacotherapy is recommended when treating opioid use disorder in pregnancy (ACOG 2017; ASAM 2020; SAMHSA 2021). Treatment should begin as early in pregnancy as possible (ASAM 2020). Buprenorphine monotherapy is generally preferred when treatment is initiated during pregnancy (ACOG 2017; ASAM 2020; SAMHSA 2021). Based on available data, an increased risk of adverse pregnancy outcomes has not been observed when pregnancy occurs during treatment with buprenorphine/naloxone combination therapy, and continued use may be considered (Ecker [SMFM 2019]; Link 2020; Link 2021).

Refer to individual monographs for additional information.

Breastfeeding Considerations

Buprenorphine and its active metabolite, norbuprenorphine, are present in breast milk. It is not known if naloxone is present in breast milk; however, systemic absorption following oral administration is limited.

According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Refer to individual monographs for additional information.

Monitoring Parameters

Liver function tests (prior to initiation and periodically during therapy); pregnancy test (prior to initiation); hepatitis and HIV tests (prior to initiation), particularly for patients with opioid use disorder (SAMHSA 2021); respiratory and mental status (especially during initiation or dose escalation); CNS depression; blood pressure; symptoms of withdrawal; signs of dependence, abuse, or misuse; signs or symptoms of hypogonadism or hypoadrenalism (Brennan 2013). Monitor for dental changes (eg, cavities, tooth erosion/decay, loss of fillings, tooth loss) with sublingual tablet use.

Mechanism of Action

Buprenorphine: Buprenorphine exerts its analgesic effect via high affinity binding to mu opiate receptors in the CNS; displays partial mu agonist and weak kappa antagonist activity

Naloxone: Pure opioid antagonist that competes and displaces opioids at opioid receptor sites

Pharmacokinetics (Adult Data Unless Noted)

Also see individual agents.

Absorption: Absorption widely is variable among patients following sublingual and buccal use, but variability within each individual patient is low.

Bioavailability:

Buccal film: The exposure of one buprenorphine 4.2 mg/naloxone 0.7 mg buccal film is equivalent to one buprenorphine 8 mg/naloxone 2 mg sublingual tablet. The naloxone exposure from buccal film was 33% less than buprenorphine/naloxone sublingual tablets. The coadministration of liquids reduced the systemic exposure up to 59% for buprenorphine and up to 76% for naloxone, depending on the pH of the liquid.

Sublingual: Although pharmacokinetics were similar between the sublingual formulations, bioequivalence is variable.

Sublingual film: Potential for greater bioavailability with certain strengths of the sublingual film compared to the same strength of the sublingual tablet. In addition, the sizes and compositions among the sublingual film strengths are different which may result in different systemic exposures.

Sublingual tablet: Zubsolv has different bioavailability when compared to other buprenorphine/naloxone sublingual tablets. One Zubsolv buprenorphine 5.7 mg/naloxone 1.4 mg sublingual tablet provides equivalent buprenorphine exposure and 12% lower naloxone exposure compared to one buprenorphine 8 mg/naloxone 2 mg sublingual tablet.

Half-life elimination: Suboxone: Buprenorphine 24 to 42 hours; Naloxone 2 to 12 hours; Bunavail: Buprenorphine 16.4 to 27.5 hours; Naloxone 1.9 to 2.4 hours.

Protein binding: Buprenorphine: ~96%, primarily to alpha and beta globulin; Naloxone: ~45%, primarily to albumin.

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Hepatic function impairment: Because both drugs are extensively metabolized, the plasma levels will be expected to be higher and the half-life values have been shown to be longer in patients with moderate and severe hepatic impairment; the significance of the effects are greater for naloxone compared to buprenorphine and for patients with severe hepatic impairment compared to patients with moderate hepatic impairment.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Suboxone;
  • (AT) Austria: Bupensan duo | Suboxone;
  • (BE) Belgium: Libroxar | Zubsolv;
  • (CH) Switzerland: Suboxone;
  • (CZ) Czech Republic: Bupensanduo | Libroxar | Zubsolv;
  • (DE) Germany: Bowielone | Bunalict | Bupensanduo | Suboxone | Zubsolv;
  • (EE) Estonia: Bupensanduo | Zubsolv;
  • (ES) Spain: Buprenorfina/Naloxona Aurovitas | Buprenorphine/naloxone tillomed | Suboxone | Zubsolv;
  • (FI) Finland: Bunalict | Buprenorphine/Naloxone G.L. Pharma | Buprenorphine/Naloxone Mylan | Suboxone | Zubsolv;
  • (FR) France: Buprenorphine/naloxone arrow | Suboxone;
  • (GB) United Kingdom: Buprenorphine/naloxone | Buprenorphine/naloxone ethypharm | Suboxone | Zubsolv;
  • (GR) Greece: Suboxone;
  • (HR) Croatia: Buprenorfin/Nalokson Mylan | Suboxone;
  • (HU) Hungary: Bulnexo | Suboxone | Suboxone Reckitt;
  • (IE) Ireland: Suboxone | Zubsolv;
  • (IN) India: Addnok n | Qudict;
  • (IT) Italy: Bunamol | Buprenorfina e naloxone ethypharm | Buprenorfina e Naloxone Mylan Pharma | Suboxone;
  • (KE) Kenya: Addnok n;
  • (KW) Kuwait: Suboxone;
  • (LT) Lithuania: Bupensanduo | Zubsolv;
  • (LU) Luxembourg: Libroxar | Suboxone;
  • (LV) Latvia: Bupensanduo | Suboxone | Zubsolv;
  • (NL) Netherlands: Bunalict | Buprenorfine/naloxon aurobindo | Buprenorfine/Naloxon Mylan | Libroxar | Suboxone | Zubsolv;
  • (NO) Norway: Bunalict | Suboxone | Zubsolv;
  • (NZ) New Zealand: Buprenorphine naloxone bnm | Temgesic-nx;
  • (PL) Poland: Suboxone;
  • (PR) Puerto Rico: Buprenorphine and naloxone | Buprenorphine hcl and naloxone hcl | Buprenorphine/naloxone | Suboxone | Zubsolv;
  • (PT) Portugal: Buprenorfin+naloxona;
  • (QA) Qatar: Suboxone;
  • (RO) Romania: Zubsolv;
  • (RU) Russian Federation: Bupraxon;
  • (SE) Sweden: Bunalict | Buprenorphine/Naloxone G.L. Pharma | Buprenorphine/Naloxone Mylan | Suboxone | Zubsolv;
  • (SI) Slovenia: Bulnexo | Suboxone | Zubsolv;
  • (SK) Slovakia: Bupensanduo;
  • (TR) Turkey: Suboxone;
  • (TW) Taiwan: Desud Plus | Suboxone;
  • (ZA) South Africa: Suboxone
  1. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
  2. Ahmedzai SH, Boland J. Constipation in people prescribed opioids. BMJ Clin Evid. 2010;2010:2407. [PubMed 21718572]
  3. Algera MH, Kamp J, van der Schrier R, et al. Opioid-induced respiratory depression in humans: a review of pharmacokinetic-pharmacodynamic modelling of reversal. Br J Anaesth. 2019;122(6):e168-e179. doi:10.1016/j.bja.2018.12.023 [PubMed 30915997]
  4. American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee opinion no. 711: opioid use and opioid use disorder in pregnancy. Obstet Gynecol. 2017;130(2):e81-e94. [PubMed 28742676]
  5. American Society of Addiction Medicine (ASAM). The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. J Addict Med. 2020;14(2S)(suppl 1):1‐91. doi:10.1097/ADM.0000000000000633 [PubMed 32511106]
  6. Aurilio C, Ceccarelli I, Pota V, et al. Endocrine and behavioural effects of transdermal buprenorphine in pain-suffering women of different reproductive ages. Endocr J. 2011;58(12):1071-1078. [PubMed 21937837]
  7. Bhatia G, Sarkar S. Sublingual buprenorphine-naloxone precipitated withdrawal - a case report with review of literature and clinical considerations. Asian J Psychiatr. 2020;53:102121. doi:10.1016/j.ajp.2020.102121 [PubMed 32460142]
  8. Bliesener N, Albrecht S, Schwager A, Weckbecker K, Lichtermann D, Klingmüller D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab. 2005;90(1):203-206. [PubMed 15483091]
  9. Bluthenthal RN, Simpson K, Ceasar RC, Zhao J, Wenger L, Kral AH. Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs. Drug Alcohol Depend. 2020;211:107932. doi:10.1016/j.drugalcdep.2020.107932 [PubMed 32199668]
  10. Boom M, Niesters M, Sarton E, Aarts L, Smith TW, Dahan A. non-analgesic effects of opioids: opioid-induced respiratory depression. Curr Pharm Des. 2012;18(37):5994-6004. doi:10.2174/138161212803582469 [PubMed 22747535]
  11. Brennan MJ. The effect of opioid therapy on endocrine function. Am J Med. 2013;126(3) (Suppl 1):S12-S18. doi: 10.1016/j.amjmed.2012.12.001. [PubMed 23414717]
  12. Bunavail (buprenorphine/naloxone) [prescribing information]. Raleigh, NC: BioDelivery Sciences International Inc; June 2022.
  13. Buprenorphine and naloxone sublingual film [prescribing information]. Pine Brook, NJ: Alvogen Inc; June 2022.
  14. Buprenorphine and naloxone sublingual tablets [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries Inc; June 2023.
  15. Buprenorphine and naloxone sublingual tablets [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries Inc; October 2023.
  16. Buprenorphine and naloxone sublingual tablets [prescribing information]. Philadelphia, PA: Lannett Company Inc; May 2022.
  17. Buprenorphine and naloxone sublingual tablets [prescribing information]. Webster Groves, MO: SpecGx LLC; November 2021.
  18. Cammarano WB, Pittet JF, Weitz S, Schlobohm RM, Marks JD. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Crit Care Med. 1998;26(4):676-684. doi:10.1097/00003246-199804000-00015 [PubMed 9559604]
  19. Cassipa (buprenorphine/naloxone) sublingual film [prescribing information]. West Caldwell, NJ: Lohmann Therapy Systems Corp (LTS); received March 2023.
  20. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2004. Report No.:(SMA) 04-3939. [PubMed 22514846]
  21. Cohen SM, Weimer MB, Levander XA, Peckham AM, Tetrault JM, Morford KL. Low dose initiation of buprenorphine: a narrative review and practical approach. J Addict Med. 2022;16(4):399-406. doi:10.1097/ADM.0000000000000945 [PubMed 34954746]
  22. Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson BJ, Sultan S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on the medical management of opioid-induced constipation. Gastroenterology. 2019;156(1):218-226. doi:10.1053/j.gastro.2018.07.016 [PubMed 30340754]
  23. Cuer JC, Dapoigny M, Ajmi S, Larpent JL, Lunaud B, Ferrier C, Bommelaer G. Effects of buprenorphine on motor activity of the sphincter of Oddi in man. Eur J Clin Pharmacol. 1989;36(2):203-204. doi:10.1007/BF00609196 [PubMed 2721544]
  24. Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology. 2010;112(1):226-238. doi:10.1097/ALN.0b013e3181c38c25 [PubMed 20010421]
  25. Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96(5):627-632. doi:10.1093/bja/ael051 [PubMed 16547090]
  26. Davis MP. Buprenorphine in cancer pain. Support Care Cancer. 2005;13(11):878-887. doi:10.1007/s00520-005-0849-9 [PubMed 16010532]
  27. De Aquino JP, Parida S, Sofuoglu M. The pharmacology of buprenorphine microinduction for opioid use disorder. Clin Drug Investig. 2021;41(5):425-436. doi:10.1007/s40261-021-01032-7 [PubMed 33818748]
  28. DeVido J, Connery H, Hill KP. Sleep-disordered breathing in patients with opioid use disorders in long-term maintenance on buprenorphine-naloxone: a case series. J Opioid Manag. 2015;11(4):363-366. [PubMed 26312963]
  29. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. MMWR Recomm Rep. 2022;71(3):1-95. doi:10.15585/mmwr.rr7103a1 [PubMed 36327391]
  30. Dunn KE, Bird HE, Bergeria CL, Ware OD, Strain EC, Huhn AS. Operational definition of precipitated opioid withdrawal. Front Psychiatry. 2023;14:1141980. doi:10.3389/fpsyt.2023.1141980 [PubMed 37151972]
  31. Ecker J, Abuhamad A, Hill W, et al. Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine. Am J Obstet Gynecol. 2019;221(1):B5-B28. doi:10.1016/j.ajog.2019.03.022 [PubMed 30928567]
  32. Etminan M, Rezaeianzadeh R, Kezouh A, Aminzadeh K. Association between sublingual buprenorphine-naloxone exposure and dental disease. JAMA. 2022;328(22):2269-2271. doi:10.1001/jama.2022.17485 [PubMed 36511932]
  33. Farmer AD, Drewes AM, Chiarioni G, et al. Pathophysiology and management of opioid-induced constipation: European expert consensus statement. United European Gastroenterol J. 2019;7(1):7-20. doi:10.1177/2050640618818305 [PubMed 30788113]
  34. FDA Drug Safety Communication. FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain. January 12, 2022. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-dental-problems-buprenorphine-medicines-dissolved-mouth-treat-opioid-use-disorder. [PubMed FDA.1]
  35. Fox LM, Hoffman RS, Vlahov D, Manini AF. Risk factors for severe respiratory depression from prescription opioid overdose. Addiction. 2018;113(1):59-66. doi:10.1111/add.13925 [PubMed 28646524]
  36. Gallagher R. Killing the symptom without killing the patient. Can Fam Physician. 2010;56(6):544-546, e210-12. [PubMed 20547520]
  37. Gupta K, Prasad A, Nagappa M, Wong J, Abrahamyan L, Chung FF. Risk factors for opioid-induced respiratory depression and failure to rescue: a review. Curr Opin Anaesthesiol. 2018;31(1):110-119. doi:10.1097/ACO.0000000000000541 [PubMed 29120929]
  38. Imam MZ, Kuo A, Ghassabian S, Smith MT. Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression. Neuropharmacology. 2018;131:238-255. doi:10.1016/j.neuropharm.2017.12.032 [PubMed 29273520]
  39. Khanna AK, Bergese SD, Jungquist CR, et al. Prediction of opioid-induced respiratory depression on inpatient wards using continuous capnography and oximetry: an international prospective, observational trial. Anesth Analg. 2020;131(4):1012-1024. doi:10.1213/ANE.0000000000004788 [PubMed 32925318]
  40. Khanna IK, Pillarisetti S. Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res. 2015;8:859-70. doi:10.2147/JPR.S85951 [PubMed 26672499]
  41. Kosten TR, Baxter LE. Review article: effective management of opioid withdrawal symptoms: a gateway to opioid dependence treatment. Am J Addict. 2019;28(2):55-62. doi:10.1111/ajad.12862 [PubMed 30701615]
  42. Lee SC, Klein-Schwartz W, Doyon S, Welsh C. Comparison of toxicity associated with nonmedical use of benzodiazepines with buprenorphine or methadone. Drug Alcohol Depend. 2014;138:118-123. doi:10.1016/j.drugalcdep.2014.02.014 [PubMed 24629782]
  43. Link HM, Jones HE, Miller LA, Kaltenbach K, Seligman NS. Buprenorphine-naloxone use in pregnancy: a subgroup analysis of medication to treat opioid use disorder. Am J Obstet Gynecol MFM. 2021;3(5):100369. doi:10.1016/j.ajogmf.2021.100369 [PubMed 33831585]
  44. Link HM, Jones H, Miller L, Kaltenbach K, Seligman N. Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis. Am J Obstet Gynecol MFM. 2020;2(3):100179. doi:10.1016/j.ajogmf.2020.100179 [PubMed 33345863]
  45. Loomis E, Bajwa J, Kaizuka S. Buprenorphine-naloxone as a novel treatment of narcotic bowel syndrome: a case report. Ann Intern Med. 2020;173(2):164-166. doi:10.7326/L19-0798 [PubMed 32422060]
  46. Lozano-López MT, Gamonal-Limcaoco S, Casado-Espada N, et al. Psychosis after buprenorphine, heroin, methadone, morphine, oxycodone, and tramadol withdrawal: a systematic review. Eur Rev Med Pharmacol Sci. 2021;25(13):4554-4562. doi:10.26355/eurrev_202107_26248 [PubMed 34286498]
  47. Marsch LA, Bickel WK, Badger GJ, Jacobs EA. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing. Drug Alcohol Depend. 2005;77(2):195-204. doi:10.1016/j.drugalcdep.2004.08.011 [PubMed 15664721]
  48. McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control. 2004;11(3 Suppl):3-9. doi:10.1177/10732748040110S302 [PubMed 15153834]
  49. Mégarbane B, Hreiche R, Pirnay S, Marie N, Baud FJ. Does high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences. Toxicol Rev. 2006;25(2):79-85. doi:10.2165/00139709-200625020-00002 [PubMed 16958555]
  50. Montandon G. The pathophysiology of opioid-induced respiratory depression. Handb Clin Neurol. 2022;188:339-355. doi:10.1016/B978-0-323-91534-2.00003-5 [PubMed 35965031]
  51. Müller-Lissner S, Bassotti G, Coffin B, et al. Opioid-induced constipation and bowel dysfunction: a clinical guideline. Pain Med. 2017;18(10):1837-1863. doi:10.1093/pm/pnw255 [PubMed 28034973]
  52. Nelson AD, Camilleri M. Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities. Therap Adv Gastroenterol. 2015;8(4):206-220. doi:10.1177/1756283X15578608 [PubMed 26136838]
  53. Oakley B, Wilson H, Hayes V, Lintzeris N. Managing opioid withdrawal precipitated by buprenorphine with buprenorphine. Drug Alcohol Rev. 2021;40(4):567-571. doi:10.1111/dar.13228 [PubMed 33480051]
  54. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(5A Suppl):11S-18S. doi:10.1016/s0002-9610(01)00782-6 [PubMed 11755892]
  55. Pattinson KT. Opioids and the control of respiration. Br J Anaesth. 2008;100(6):747-758. doi:10.1093/bja/aen094 [PubMed 18456641]
  56. Pattullo GG. Clinical implications of opioid-induced ventilatory impairment. Anaesth Intensive Care. 2022;50(1-2):52-67. doi:10.1177/0310057X211070292 [PubMed 35189729]
  57. Prielipp RC, Fulesdi B, Brull SJ. Postoperative opioid-induced respiratory depression: 3 steps forward. Anesth Analg. 2020;131(4):1007-1011. doi:10.1213/ANE.0000000000005098 [PubMed 32925317]
  58. Quattlebaum THN, Kiyokawa M, Murata KA. A case of buprenorphine-precipitated withdrawal managed with high-dose buprenorphine. Fam Pract. 2022;39(2):292-294. doi:10.1093/fampra/cmab073 [PubMed 34173647]
  59. Refer to manufacturer's labeling.
  60. Reindel KL, DeAngelis MJ, Ferrara AS, et al. An exploratory study of Suboxone (buprenorphine/naloxone) film splitting: cutting methods, content uniformity, and stability. Int J Pharm Compd. 2019;23(3):258-263. [PubMed 31085795]
  61. Richards S, Torre L, Lawther B. Buprenorphine-related complications in elderly hospitalised patients: a case series. Anaesth Intensive Care. 2017;45(2):256-261. doi:10.1177/0310057X1704500217 [PubMed 28267949]
  62. Rosado J, Walsh SL, Bigelow GE, Strain EC. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depend. 2007;90(2-3):261-269. doi:10.1016/j.drugalcdep.2007.04.006 [PubMed 17517480]
  63. Rossi M, Casale G, Badiali D, et al. Opioid-induced bowel dysfunction: suggestions from a multidisciplinary expert Board. Support Care Cancer. 2019;27(11):4083-4090. doi:10.1007/s00520-019-04688-2 [PubMed 30778756]
  64. Smith K, Hopp M, Mundin G, et al, "Low Absolute Bioavailability of Oral Naloxone in Healthy Subjects," Int J Clin Pharmacol Ther, 2012, 50(5):360-7. [PubMed 22541841]
  65. Spadaro A, Long B, Koyfman A, Perrone J. Buprenorphine precipitated opioid withdrawal: Prevention and management in the ED setting. Am J Emerg Med. 2022;58:22-26. doi:10.1016/j.ajem.2022.05.013 [PubMed 35623179]
  66. Suboxone (buprenorphine/naloxone) sublingual film [prescribing information]. North Chesterfield, VA: Indivior Inc; received March 2023.
  67. Suboxone (buprenorphine/naloxone) sublingual film and sublingual tablet [product monograph]. Toronto, Ontario, Canada: Pharma Importing Inc; March 2023.
  68. Substance Abuse and Mental Health Services Administration (SAMHSA). Medications for opioid use disorder. Treatment Improvement Protocol (TIP) Series 63 Publication No. PEP21-02-01-002. https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-002.pdf. Published 2021. Accessed September 30, 2021.
  69. Suzuki J, Mittal L, Woo SB. Sublingual buprenorphine and dental problems: a case series. Prim Care Companion CNS Disord. 2013;15(5):PCC.13l01533. doi:10.4088/PCC.13l01533 [PubMed 24511440]
  70. Suzuki J, Park EM. Buprenorphine/naloxone and dental caries: a case report. Am J Addict. 2012;21(5):494-495. doi:10.1111/j.1521-0391.2012.00254.x [PubMed 22882403]
  71. Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician. 2006;74(8):1347-1354. [PubMed 17087429]
  72. US Food and Drug Administration (FDA). FDA drug safety communication: FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use. Published April 13, 2023. Accessed April 17, 2023.
  73. van Dorp E, Yassen A, Sarton E, et al. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology. 2006;105(1):51-57. doi:10.1097/00000542-200607000-00012 [PubMed 16809994]
  74. Varga AG, Reid BT, Kieffer BL, Levitt ES. Differential impact of two critical respiratory centres in opioid-induced respiratory depression in awake mice. J Physiol. 2020;598(1):189-205. doi:10.1113/JP278612 [PubMed 31589332]
  75. Velázquez Rivera I, Velázquez Clavarana L, García Velasco P, Melero Ramos C. Opioid-induced constipation in chronic pain: experience with 180 patients. J Opioid Manag. 2019;15(1):69-76. doi:10.5055/jom.2019.0487 [PubMed 30855724]
  76. Viswanath A, Barreveld AM, Fortino M. Assessment and management of the high-risk dental patient with active substance use disorder. Dent Clin North Am. 2020;64(3):547-558. doi:10.1016/j.cden.2020.02.004 [PubMed 32448458]
  77. Wang PP, Huang E, Feng X, et al. Opioid-associated iatrogenic withdrawal in critically ill adult patients: a multicenter prospective observational study. Ann Intensive Care. 2017;7(1):88. doi:10.1186/s13613-017-0310-5 [PubMed 28866754]
  78. Webster LR, Camilleri M, Finn A. Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals. Subst Abuse Rehabil. 2016;7:81-86. doi:10.2147/SAR.S100998 [PubMed 27366109]
  79. Whitley SD, Sohler NL, Kunins HV, et al. Factors associated with complicated buprenorphine inductions. J Subst Abuse Treat. 2010;39(1):51-57. doi:10.1016/j.jsat.2010.04.001 [PubMed 20682186]
  80. Wiegand SL, Swortwood MJ, Huestis MA, Thorp J, Jones HE, Vora NL. Naloxone and metabolites quantification in cord blood of prenatally exposed newborns and correlations with maternal concentrations. AJP Rep. 2016;6(4):e385-e390. [PubMed 27896019]
  81. Yazdanian M, Armoon B, Noroozi A, et al. Dental caries and periodontal disease among people who use drugs: a systematic review and meta-analysis. BMC Oral Health. 2020;20(1):44. doi:10.1186/s12903-020-1010-3 [PubMed 32041585]
  82. Zoorob R, Kowalchuk A, Mejia de Grubb M. Buprenorphine therapy for opioid use disorder. Am Fam Physician. 2018;97(5):313-320. [PubMed 29671504]
  83. Zubsolv (buprenorphine/naloxone) [prescribing information]. Morristown, NJ: Orexo US Inc; June 2022.
  84. Zubsolv (buprenorphine/naloxone) [prescribing information]. Morristown, NJ: Orexo US Inc; March 2023.
Topic 8788 Version 528.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟